版本:
中国

BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress

Oct 7 Seattle Genetics Inc :

* Seattle Genetics and Agensys, an affiliate of Astellas, highlight promising enfortumab vedotin (ASG-22ME) and ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐